Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have been assigned an average rating of “Buy” from the fifteen brokerages that are currently covering the company, Marketbeat reports. Six analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $60.73.
Several equities research analysts recently commented on ESPR shares. Northland Securities reissued a “buy” rating and set a $72.00 target price on shares of Esperion Therapeutics in a report on Friday, November 10th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $70.00 price target on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Cowen and Company began coverage on Esperion Therapeutics in a report on Thursday, September 7th. They issued an “outperform” rating and a $64.00 price target on the stock. Zacks Investment Research raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $85.00 price target on shares of Esperion Therapeutics in a report on Monday, August 21st.
Shares of Esperion Therapeutics (NASDAQ:ESPR) traded down $0.30 during mid-day trading on Monday, reaching $49.19. The company’s stock had a trading volume of 274,678 shares, compared to its average volume of 1,047,633. Esperion Therapeutics has a 12 month low of $10.30 and a 12 month high of $57.40.
A number of institutional investors have recently modified their holdings of the business. Meditor Group Ltd grew its stake in Esperion Therapeutics by 305.5% during the third quarter. Meditor Group Ltd now owns 2,294,935 shares of the biopharmaceutical company’s stock worth $115,022,000 after buying an additional 1,728,935 shares during the last quarter. BB Biotech AG grew its stake in Esperion Therapeutics by 7.5% during the second quarter. BB Biotech AG now owns 1,513,542 shares of the biopharmaceutical company’s stock worth $70,047,000 after buying an additional 105,000 shares during the last quarter. State Street Corp grew its stake in shares of Esperion Therapeutics by 264.6% during the second quarter. State Street Corp now owns 1,506,514 shares of the biopharmaceutical company’s stock valued at $69,721,000 after purchasing an additional 1,093,292 shares during the last quarter. FMR LLC grew its stake in shares of Esperion Therapeutics by 2.3% during the second quarter. FMR LLC now owns 1,338,588 shares of the biopharmaceutical company’s stock valued at $61,950,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Discovery Capital Management LLC CT grew its stake in shares of Esperion Therapeutics by 152.9% during the second quarter. Discovery Capital Management LLC CT now owns 965,059 shares of the biopharmaceutical company’s stock valued at $44,663,000 after purchasing an additional 583,529 shares during the last quarter. 89.12% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: This article was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://sportsperspectives.com/2017/11/18/esperion-therapeutics-inc-espr-given-average-rating-of-buy-by-brokerages.html.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.